Zoetis earnings were $2.6B for the trailing 12 months ending Jun 30, 2025, with 13.9% growth year over year. The latest ZTS earnings report on Jun 30, 2025 announced Q2 2025 earnings of $718.0M, up 13.8% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, ZTS reported annual earnings of $2.5B, with 6.1% growth.
ZTS past earnings growth
How has ZTS's earnings growth performed historically?
On ZTS's earnings call on Invalid Date, Zoetis (NYSE: ZTS) reported Q2 2025 earnings per share (EPS) of $1.61, up 17.52% year over year. Total ZTS earnings for the quarter were $718.00 million. In the same quarter last year, Zoetis's earnings per share (EPS) was $1.37.
As of the last Zoetis earnings report, Zoetis is currently profitable. Zoetis's net profit (also called net income) for the twelve months ending Jun 30, 2025 was $2.61 billion, a 11.43% increase year over year.
What was ZTS's earnings growth in the past year?
As of Zoetis's earnings date in Invalid Date, Zoetis's earnings has grown 13.89% year over year. This is 4.79 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry earnings growth rate of 18.68%. ZTS earnings in the past year totalled $2.61 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.